title: Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
authors.forename: Koen
authors.initials: K
authors.lastname: Van Besien
authors.forename: Sonali
authors.initials: S
authors.lastname: Smith
authors.forename: John
authors.initials: J
authors.lastname: Anastasi
authors.forename: Richard
authors.initials: R
authors.lastname: Larson
authors.forename: Michael
authors.initials: M
authors.lastname: Thirman
authors.forename: Toyosi
authors.initials: T
authors.lastname: Odenike
authors.forename: Wendy
authors.initials: W
authors.lastname: Stock
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D042381:Granulocyte Precursor Cells / Q000187:drug effects; D006402:Hematologic Diseases / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008558:Melphalan / Q000009:adverse effects*; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan